Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023

Perry Elliott, MD, FRCP - What’s New and What’s Next? Expanding Our Understanding of HCM in 2023...

8 months ago

24:37

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations

Edward B. Garon, MD, MS - Abundance of Choice at First Line, Lack of Options Beyond: Addressing Unmet Needs in NSCLC Without Actionable Mutations...

8 months ago

20:40

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD

Claus Vogelmeier, MD - Approaching Airway Inflammation From Another Angle: The Rationale for Targeting Type 2 Pathways in COPD...

8 months ago

20:54

Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations

Perry Elliott, MD, FRCP - Continuing Our Conversation in HCM: Compelling Questions and Evolving Considerations...

8 months ago

13:13

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers

Laura Obici, MD - Taking Action to Improve the Patient Journey With Transthyretin Amyloidosis (ATTR): Shared Perspectives From Patients and Providers...

9 months ago

38:10

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting

David Planchard, MD, PhD - Catching Up on CEACAM5 in NSCLC: The Whys and Hows of Detection and Targeting...

11 months ago

44:29

Wong Seng Weng, MBBS, MRCP, FAMS - Treatment Approaches in EGFR-Mutant NSCLC Post-TKI and Chemotherapy: What Now and What Next?

PeerVoice Heart & Lung Audio